Classical Hodgkin Lymphoma Clinical Trials

14 recruiting

Classical Hodgkin Lymphoma Trials at a Glance

15 actively recruiting trials for classical hodgkin lymphoma are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Cologne, Padova, and Boston. Lead sponsors running classical hodgkin lymphoma studies include Sun Yat-sen University, University of Cologne, and Baylor College of Medicine.

Browse classical hodgkin lymphoma trials by phase

Treatments under study

About Classical Hodgkin Lymphoma Clinical Trials

Looking for clinical trials for Classical Hodgkin Lymphoma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Classical Hodgkin Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Classical Hodgkin Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 2Phase 3

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

TreatmentSurvivalClassical Hodgkin Lymphoma+6 more
Children's Cancer Group, China96 enrolled1 locationNCT06563245
Recruiting
Phase 1Phase 2

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

MelanomaSolid TumorLymphoma+2 more
Merck Sharp & Dohme LLC370 enrolled17 locationsNCT02332668
Recruiting

European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma
Assistance Publique - Hôpitaux de Paris400 enrolled1 locationNCT07356882
Recruiting
Phase 1

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Chronic Myeloid LeukemiaMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics130 enrolled7 locationsNCT05362773
Recruiting
Not Applicable

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Classical Hodgkin Lymphoma
Fondazione Italiana Linfomi - ETS552 enrolled40 locationsNCT05934084
Recruiting
Phase 2

Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT06393361
Recruiting
Phase 1

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin LymphomaExtranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Baylor College of Medicine18 enrolled2 locationsNCT04288726
Recruiting

Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma

Classical Hodgkin LymphomaClassical Hodgkin Lymphoma RecurrentClassical Hodgkin Lymphoma Refractory
Azienda USL Reggio Emilia - IRCCS755 enrolled12 locationsNCT06822855
Recruiting
Phase 2

Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study

Classical Hodgkin Lymphoma
Sun Yat-sen University73 enrolled1 locationNCT06848569
Recruiting
Phase 2

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma
University of Cologne29 enrolled1 locationNCT04838652
Recruiting
Phase 2

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma
University of Cologne120 enrolled1 locationNCT04837859
Recruiting
Phase 2

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Classical Hodgkin Lymphoma
University of Virginia44 enrolled3 locationsNCT05404945
Recruiting
Phase 2

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Refractory CancerClassical Hodgkin LymphomaRelapsed Cancer
University Health Network, Toronto37 enrolled1 locationNCT04510636
Recruiting
Phase 2

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Classical Hodgkin Lymphoma
Sun Yat-sen University54 enrolled1 locationNCT05900765
Recruiting
Phase 2

Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

Relapsed/Refractory Classical Hodgkin Lymphoma
National Cancer Center, Korea30 enrolled1 locationNCT05243693